Teva同意将其日本合资企业Teva-Takeda出售给JKI有限公司,侧重于增长。 Teva agrees to sell its Japan venture, Teva-Takeda, to JKI Co., Ltd., focusing on growth.

Teva制药工业有限公司已同意将其设在日本的经营企业Teva-Takeda出售给J-Will合伙人有限公司设立的一家公司JKI公司。 Teva Pharmaceutical Industries Ltd. has agreed to sell its Japan-based business venture, Teva-Takeda, to JKI Co., Ltd., a company set up by J-Will Partners Co., Ltd. 这一举措是Teva注重增长战略的一部分,预计到2025年4月1日结束,等待监管批准。 This move, part of Teva's strategy to focus on growth, is expected to close by April 1, 2025, pending regulatory approval. 所有现任雇员将保留在新所有权之下的职位。 All current employees will retain their positions under the new ownership.